Antibody-Drug Conjugates (ADCs) have revolutionized oncology, earning their reputation as biological "Trojan horses." By tethering a highly potent cytotoxic payload to a target-specific monoclonal antibody, ADCs promise to deliver chemotherapy directly to malignant cells while sparing healthy tissues.
However, translating this elegant concept into a safe, clinically viable therapeutic is...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)